Production (Stage)
Ensysce Biosciences, Inc.
ENSC
$2.07
-$0.07-3.27%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -6.82M | -7.99M | -7.93M | -11.28M | -11.54M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 25.70K | 1.20M | 1.52M | 1.52M | 1.50M |
| Total Other Non-Cash Items | 142.30K | 138.70K | 724.30K | 750.60K | 756.70K |
| Change in Net Operating Assets | 846.30K | -851.30K | -2.86M | -779.10K | -1.29M |
| Cash from Operations | -5.80M | -7.50M | -8.54M | -9.78M | -10.58M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | 1.61M | 1.61M | 1.61M |
| Total Debt Repaid | -266.10K | -857.80K | -906.00K | -937.10K | -1.47M |
| Issuance of Common Stock | 3.48M | 4.10M | 3.75M | 2.08M | 8.44M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 2.24M | 6.64M | 6.78M | 4.25M | 4.00M |
| Cash from Financing | 5.45M | 9.88M | 11.23M | 7.00M | 12.57M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -351.80K | 2.38M | 2.69M | -2.79M | 1.99M |